1.Revised PhilHealth Case Rates for Hospitalization for Acute Coronary Syndrome in the Philippines.
Felix Eduardo R PUNZALAN ; Noemi S PESTAÑO ; April Ann A BERMUDEZ-DELOS SANTO ; Bernadette A TUMANAN-MENDOZA ; Victor L MENDOZA ; Eric Oliver D SISON ; Karen AMOLOZA-DE LEON ; Eugenio B REYES ; Nashiba M DAUD ; Maria Grethel C DIMALALA-LARDIZABAL ; Orlando R BUGARIN ; Rodney M JIMENEZ ; Domicias L ALBACITE ; Ma. Belen A BALAGAPO ; Elfred M BATALLA ; Jonathan James G BERNARDO ; Helen Ong GARCIA ; Amibahar J KARIM ; Gloria R LAHOZ ; Neil Wayne C SALCES
Philippine Journal of Cardiology 2022;50(2):25-25
BACKGROUND: Hospitalization for acute coronary syndrome (ACS) has epidemiologic and economic burden. The coverage for hospitalization in the local setting is much less than the actual costs. Many patients do not consent to or avail of the optimal and timely management because of financial challenges.
OBJECTIVES: The paper aimed to propose revised PhilHealth case rates/packages for ACS, namely: 1) unstable angina (UA), 2) non-ST-elevation myocardial infarction (NSTEMI), and 3) STelevation myocardial infarction (STEMI).
METHODS: A consensus panel was organized to provide inputs such as cost and other matters pertaining to the revision of the PhilHealth ACS case rates/packages. The results of the cost of hospitalization of the different ACS conditions derived from a study on hospitalization cost for ACS were presented to the panel. Several focused group discussions were held afterward for propositioning new case rates through votation and by nominal group technique, using the costs from the study as the bases of rate adjustment.
RESULTS: Final costs agreed upon by the consensus panel for medical management alone for UA, NSTEMI, and STEMI were adjusted or amended in increments of Php 20,000, (80,000, 100,000, and 120,000, respectively). Thrombolysis of a patient admitted for STEMI increased the cost to Php 140,000. An additional cost of Php 150,000 was added on top of the cost for medical management and coronary angiogram for NSTE- ACS for PCI with use of a single stent. For STEMI, the same category had an additional cost of Php 180,000. For each additional stent used for all clinical scenarios undergoing PCI, Php 65,000 was added, to cover up to a total of 3 stents.
CONCLUSION: Based on the consensus process with Philippine Heart Association ACS panelists, the cost proposed ranges from 80,000 pesos to 530,000 pesos depending on the clinical scenarios.
KEYWORDS: case rates, PhilHealth, acute coronary syndrome, economic impact
2.Budget Impact Analysis of the Proposed PhilHealth Case Rates for Acute Coronary Syndrome in the Philippines.
Bernadette A TUMANAN-MENDOZA ; Victor L MENDOZA ; Felix Eduardo R PUNZALAN ; Noemi S PESTAÑO ; April Ann A BERMUDEZ-DELOS SANTO ; Eric Oliver D SISON ; Eugenio B REYES ; Karen AMOLOZA-DE LEON ; Nashiba M DAUD ; Maria Grethel C DIMALALA-LARDIZABAL ; Orlando R BUGARIN ; Rodney M JIMENEZ ; Domicias L ALBACITE ; Ma. Belen A BALAGAPO ; Elfred M BATALLA ; Jonathan James G BERNARDO ; Helen Ong GARCIA ; Amibahar J KARIM ; Gloria R LAHOZ ; Neil Wayne C SALCES
Philippine Journal of Cardiology 2022;50(2):33-33
OBJECTIVE: This study aimed to determine the budget impact of the proposed revised PhilHealth case rate packages for acute coronary syndrome (ACS).
METHODS: This budget impact analysis used the static approach or cost calculator modeling method. The prevalence of hospitalization for coronary artery disease in all PhilHealth-accredited hospitals in the country in 2017 and the data from the ACS registry project of the Philippine Heart Association were used in this study. The study multiplied the present PhilHealth coverage with the number of ACS hospitalization claims to come up with the total cost of ACS hospitalization in the next three years with the assumptions that the eligible population and the ACS PhilHealth case rates will remain constant for these years. The future ACS hospitalization costs were also determined if the proposed case rates were used rather than the current PhilHealth case rates. The cost of re-admissions was considered as savings in hospitalization cost (due to prevention of admissions if the appropriate interventions were given) and were deducted from the future total cost of ACS hospitalizations.
RESULTS: The annual total ACS hospitalization cost using the current case rates was Php 1,134,683,000. Using the proposed case rates, the total hospitalization costs over five years was Php 2,653,019,000 in the first year (proposed case rates implemented to only 20% of the ACS patients) and increased to Php 8,726,364,000 by year 5 (full implementation of the proposed case rates or to 100% of ACS patients). This resulted in a lower incremental cost in the first year of implementation compared with a less gradual implementation over 3 years. The total incremental costs would amount to PHP7.6 billion for full implementation.
CONCLUSION: The study provided the budget impact of the proposed revised ACS case rates. The incremental cost is relatively huge, however the benefits of providing coverage of guidelinedirected therapy including invasive strategies for ACS must be considered.